elderly patients – Medxy AI

Multicomponent Pulmonary Rehabilitation Significantly Enhances Weaning Outcomes in Elderly Patients on Prolonged Mechanical Ventilation

By MedXY 09/30/2026

A randomized controlled trial demonstrates that a multicomponent pulmonary rehabilitation program markedly improves ventilator weaning success and physiological recovery in patients aged 80 and older undergoing prolonged mechanical ventilation.

Hematology-Oncology news Oncology

First-line Ibrutinib Plus Venetoclax in Nonblastoid Mantle Cell Lymphoma: Efficacy and Safety in Older Adults and TP53-Mutant Patients

By MedXY 09/22/2026

The phase 3 SYMPATICO trial demonstrated that first-line combination therapy with ibrutinib and venetoclax yields high complete response rates and durable remissions in patients ≥65 years or with TP53 mutations suffering from nonblastoid mantle cell lymphoma.

General Surgery news Oncology

Balancing Efficacy and Safety: Neoadjuvant Immunochemoradiotherapy vs. Immunochemotherapy in Elderly Esophageal Squamous Cell Carcinoma

By MedXY 09/14/2026

In elderly patients with locally advanced esophageal squamous cell carcinoma, neoadjuvant immunochemoradiotherapy offers superior tumor response but increases surgical complexity and cardiac risks compared to immunochemotherapy. Personalized treatment decisions are critical.

Cardiology Clinical Updates news

Temporal Trends in Oral Anticoagulant Use and Clinical Outcomes Among Older Adults with Atrial Fibrillation: Insights from a Danish Nationwide Study and Contemporary Evidence

By MedXY 07/16/2026

Recent decades saw increased anticoagulant use and reduced stroke risk in elderly AF patients, especially with DOACs, but bleeding risks rise notably in very elderly patients, highlighting tailored management needs.

Clinical Updates Hematology-Oncology news

Long-term Outcomes of Oral Decitabine/Cedazuridine Plus Venetoclax in Older or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

By MedXY 07/09/2026

Oral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particular challenges in secondary AML.